Juvéderm Volux XC is said to be the first and only hyaluronic acid (HA) filler to receive US FDA approval for improving jawline definition, and sixth product in the company’s Juvéderm family of fillers
Allergan Aesthetics, a subsidiary of AbbVie, announced that the US FDA has approved its Juvéderm Volux XC for improving jawline definition in adults, aged 21 years and above.
Juvéderm Volux XC is the latest addition to the company’s Juvéderm family of fillers.
It is the sixth product in the portfolio, alongside Juvéderm Voluma XC, Juvéderm Vollure XC, Juvéderm Ultra Plus XC, Juvéderm Ultra XC, and Juvéderm Volbella XC.
The Juvéderm Volux XC is the first and only hyaluronic acid (HA) filler to get FDA approval for improving jawline definition, said Allergan Aesthetics.
Allergan Aesthetics global president and AbbVie senior vice president Carrie Strom said: “The approval of Juvéderm Volux XC represents the largest leap in innovation for our U.S. HA portfolio since the introduction of Juvéderm Voluma XC.
“Juvéderm Volux XC complements our existing product line to provide even more structure, cohesivity and lift capacity to create an improved jawline that appears more defined in real life and on camera.
“Juvéderm Volux XC is what our providers have been asking for to deliver the jaw-dropping results their patients are seeking.”
In the clinical study, participants who received Juvéderm Volux XC experienced an effective improvement of jawline definition at six months.
The participants’ satisfaction through 12 months was determined using the Satisfaction with Lower Face and Jawline module of the FACE-Q questionnaire.
In the study, 81.5% of participants were satisfied with how sculpted (well-defined) their jawline looked at six months, compared to 12.2% at baseline.
The study revealed that 70.5% of participants were satisfied with how smooth their lower face looked, without jowls or folds of fatty skin, compared to 7.7% at baseline.
In addition, 73.1% of participants were satisfied with how nice their lower face looked compared to 9.0% at baseline, at six months.
Tenderness, lumps, pain, swelling, firmness, bruising, redness, itching, and discolouration at the injection sites, include the commonly reported side effects in the clinical study.
Clinical trial investigator Jeremy Green said: “Requests for treatment in the lower facial region transcend age, gender, race, and ethnicity in my practice. As people age, many factors can contribute to how the lower face changes, such as genetics and soft tissue loss.
“This can cause reduced definition around the jawline area that may impact and change the shape of the face and lead to the appearance of jowls. Clinical trial participants reported high satisfaction with the results of their treatment.”
Earlier this year, Allergan Aesthetics received US FDA approval for Juvéderm Volbella XC to improve infraorbital hollows in adults older than 21 years.